Compare Eli Lilly And Co (LLY) vs Paychex, Inc. (PAYX) Price & Performance

Eli Lilly (LLY) trades at $1,150.86, down 2.39% on the day, with a bullish technical signal from moving averages and strong fundamental performance. The company reported robust earnings beats in recent quarters, with Q1 2026 EPS of $8.55 exceeding expectations by 23%. Revenue surged to $65.18 billion in 2025, driving a net income margin of 34.99%. Recent news highlights LLY's $2.8 billion acquisition of AtaiBeckley to expand its neuroscience pipeline, signaling strategic growth in mental health treatments.

Outlook remains positive with analyst consensus price target of $1,380 implying 20% upside, supported by 73% buy ratings. Key risks include high valuation multiples (P/E 41.89) and rising debt levels, though operating cash flow growth to $16.81 billion in 2025 provides financial flexibility. Investors should monitor Q2 2026 earnings on August 5 for continued execution on weight-loss drug demand and integration of recent acquisitions.

Paychex (PAYX) trades at $115.15, up 0.66% today, with strong technical momentum indicated by bullish moving averages. The company demonstrates robust fundamentals with consistent earnings beats, including Q1 2026 EPS of $1.32 beating expectations of $1.31, and maintains high profitability with a 27.03% net income margin. Recent developments include dividend declarations and positive small business job growth trends.

Outlook remains positive with steady revenue growth and AI expansion driving future performance, though valuation metrics appear elevated with P/E at 23.39. Key risks include macroeconomic sensitivity to small business hiring and competitive pressures. Analyst consensus is mixed with 63.33% hold ratings and a $110 price target slightly below current levels.